Stock Events

Stock Events

InMed Pharmaceuticals 

$1.3750
39
+$0.01+1.1% Tuesday 20:00
-$0.04-3.27%Tuesday 23:00After hours

Statistics

Day High
1.395
Day Low
1.38
52W High
2.5
52W Low
0.575
Volume
1,451
Avg. Volume
-
Mkt Cap
7.55M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6NovExpected
Q3 2024
Q4 2024
Q1 2025
Q3 2025
Q4 2025
Q1 2026
Next
-3.64
-2.66
-1.67
-0.69
Expected EPS
N/A
Actual EPS
N/A

Financials

-409.1%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
3.18MRevenue
-12.99MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow INM. It's not an investment recommendation.
Bitcoin
5
BTC.CRYPTO
AGNC Investment
5
AGNC
Meta Platforms
5
META
Gamestop
5
GME

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Corbus Pharmaceuticals
CRBP
Mkt Cap138.1M
Corbus Pharmaceuticals specializes in the development of drugs targeting inflammatory and fibrotic diseases, overlapping with InMed's therapeutic areas.
Aurora Cannabis
ACB
Mkt Cap259.57M
Aurora Cannabis is a major player in the cannabis industry, whose expansion into medical cannabis products puts it in direct competition with InMed's pharmaceutical cannabis products.
Tilray Brands
TLRY
Mkt Cap579.95M
Tilray is a global leader in cannabis research, cultivation, processing, and distribution, potentially competing with InMed in the medical cannabis market.
Canopy Growth
CGC
Mkt Cap398.29M
Canopy Growth Corporation operates in the cannabis and hemp business, competing with InMed in the development of cannabinoid-based pharmaceuticals.
Curaleaf
CURLF
Mkt Cap2.5B
Curaleaf Holdings operates in the cannabis retail and medical cannabis oil production, competing with InMed in the cannabinoid-based product market.

About

InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
Show more...
CEO
Eric A. Adams Chem.
Employees
6
Country
Canada
ISIN
CA4576377002
WKN
000A40UCN

Listings

MU
DE
MWG2.MU
F
DE
MWG.F
XNAS
US
INM
STU
DE
MWG.STU

0 Comments

Share your thoughts

FAQ

What is InMed Pharmaceuticals stock price today?▼
The current price of INM is $1.38 USD — it has increased by +1.1% in the past 24 hours. Watch InMed Pharmaceuticals stock price performance more closely on the chart.
What is InMed Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange InMed Pharmaceuticals stocks are traded under the ticker INM.
Is InMed Pharmaceuticals stock price growing?▼
INM stock has fallen by -0.36% compared to the previous week, the month change is a -0.36% fall, over the last year InMed Pharmaceuticals has showed a -37.21% decrease.
What is InMed Pharmaceuticals market cap?▼
Today InMed Pharmaceuticals has the market capitalization of 7.55M
When is the next InMed Pharmaceuticals earnings date?▼
InMed Pharmaceuticals is going to release the next earnings report on November 06, 2026.
What were InMed Pharmaceuticals earnings last quarter?▼
INM earnings for the last quarter are -0.69 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is InMed Pharmaceuticals revenue for the last year?▼
InMed Pharmaceuticals revenue for the last year amounts to 3.18M USD.
What is InMed Pharmaceuticals net income for the last year?▼
INM net income for the last year is -12.99M USD.
How many employees does InMed Pharmaceuticals have?▼
As of September 30, 2026, the company has 6 employees.
In which sector is InMed Pharmaceuticals located?▼
InMed Pharmaceuticals operates in the Health & Wellness sector.
When did InMed Pharmaceuticals complete a stock split?▼
The last stock split for InMed Pharmaceuticals was on November 14, 2024 with a ratio of 1:20.
Where is InMed Pharmaceuticals headquartered?▼
InMed Pharmaceuticals is headquartered in VANCOUVER, Canada.